[ad_1]
Pfizer and Biontech emphasize that all essential requirements for the new vaccine have already been met. Now only approval, production and distribution remain.
“Pfixer and Biontech are completing phase 3 studies of the covid -19 candidate vaccine, meeting all important requirements,” the headline of the press release from the two pharmaceutical companies reads.
– The studies mark an important step in the historic eight-month journey to obtain a vaccine that can help end this devastating pandemic. We will continue as soon as the investigation allows us to gather all the data we have collected so far and share it with regulators around the world. Hundreds of thousands of people around the world are infected daily, and it is urgent to provide the world with a safe and effective vaccine, says Albert Bourla, Pfizer’s chief Greek-American manager, in the press release.
The two companies emphasize that all the safety requirements of the US health authorities (FDA and US) are met.
Final analyzes show 95 percent efficacy of the coronary vaccine in which pharmaceutical companies Pfizer from the US and Biontech from Germany collaborate. Preliminary tests showed at least 90 percent efficiency.
- The price of oil immediately bounces more than two percent after the announcement and is trading as high as $ 45 a barrel.
- Key indices on Wall Street are rising ahead of trading on the news. The Oslo Stock Exchange also moved up some notches.
- The company will request approval of the vaccine in a few days.
Pfizer writes in a press release that together with Biontech they hope to produce 50 million doses of vaccines this year and up to 1.3 billion doses in 2021. Two doses of vaccine are required per person.
The vaccine will be produced in laboratories and factories in the US, Germany and Belgium.
Competitors are right behind
American competitor Moderna arrived earlier this week with a vaccine that shows a preliminary efficiency of 94.5 percent.
Russia’s Sputnik has previously reported 92 percent efficacy for its vaccine, which is still in doubt, especially in the West.
China’s Sinovac Biotech announced on Wednesday a serious setback in the development of its coronary vaccine.(Terms)Copyright Dagens Næringsliv AS and / or our suppliers. We would like you to share our cases via a link, which leads directly to our pages. Copying or other use of all or part of the content can only be done with written permission or as permitted by law. For more terms, see here.
